Breast Cancer - Triple Negative - KOL Insight

From the growing enthusiasm for a potential subcutaneous formulation of Keytruda, the cautious optimism surrounding the outcomes of Cosela's PRESERVE 2 trial, and the promising future of datopotamab deruxtecan, explore the forefront of triple-negative breast cancer (TNBC) treatment advancements. KOLs provide a comprehensive analysis on the evolving landscape of TNBC therapy, emphasizing the significant impact these developments could have on patient care and treatment outcomes. Discover how these innovations are poised to transform the TNBC treatment paradigm.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key brands covered in this report:

Key questions answered:

• Which drug is the treatment of choice for each patient segment, line of therapy and unique patient characteristic, and what product attributes contribute to the preference?
• How is the product perceived by the medical community in terms of efficacy, tolerability, ease of administration and other product attributes, and how does it compare with other treatment options?
• Which recently completed or ongoing clinical trials have the greatest potential to impact prescribing trends, and how will the results impact practice in the future (e.g. PERSEVERE, neoBREASTIM, OptimICE-PCT, PRESERVE 2, ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast04, TROPION-Breast05, etc.)?
• What will a product need to show in order to become the treatment of choice in a specific line of therapy, and is it likely that the product will meet these requirements?
• How will the use of each product change in the future in terms of line of therapy and preference?
• What will the pipeline products need to show in terms of efficacy and tolerability endpoints to effectively compete with current therapies, and what is the likelihood that they will achieve those endpoints?